| October 23, 2013 |
| 11.00 |
Registrazione |
|
|
|
|
|
|
| 14.00 |
Tavola rotonda
"Il ruolo del farmaco per la salute e la crescita in Italia" |
|
|
|
|
|
|
| 15.00 |
NS23
SIF - SSFA Symposium: Clinical
Research in Italy: how to compete? |
MS4
Innovation and technology for a competitive and sustainable health care system |
NS13
Nanomedicines for cancer therapy |
C2
Oral
Communications
Stroke and Neuroinflammation |
|
MS10
Rifaximin, an Ever Green Antibiotic: New Insights and New Therapeutic Applications
(15.00-16.30) |
|
| 16.00 |
|
|
|
| 17.00 |
Welcome Ceremony |
|
|
|
|
|
|
| 18.00 |
Lectio Magistralis
Pasinelli |
|
|
|
|
|
|
| October 24, 2013 |
| 8.30 |
C5 Oral
Communications
Pharmaco-
epidemiology nd Pharmacovigilance |
NS25
Inflammation and vulnerability to neuropsychiatric disorders: molecular mechanisms and clinical outcomes |
NS16
Neurodegenerative diseases and brain injury: from cellular and molecular mechanisms to new neuroprotective strategies |
|
C3 Oral
Communications
Personalized Medicine |
C4 Oral
Communications
Inflammations Pharmacology |
C6 Oral
Communications
Metabolism Pharmacology |
| 9.30 |
L16
Omega-3 fatty
acids in cardiovascular
prevention: how and when? |
| 10.00 |
| 10.30 |
Coffee break |
| 11.00 |
|
NS1
SIF-SINPF-SIP-SITOX Neurobiological
and Clinical Continuum
Between
Psychopathology on Abuse of Substances |
S1
Pharmacological
innovation in onco-hematology |
S6
Pharmacological
management of
patients at high cardiovascular risk |
NS5
Aspetti farmacologi, clinici e
regolatori delle Tossine Botuliniche |
L20
Innovation in the treatment of IBD |
|
| 11.30 |
S5
Innovation beyond biotechnological drugs: the role of small molecules as target therapy |
| 12.00 |
S4 Adherence and economic sustainability in
cardiovascular treatment |
| 12.30 |
| 13.00 |
|
Pipeline lunch |
|
|
|
|
Assemblea Sezione di Farmacologia Clinica |
| 14.00 |
Lectio Magistralis
Marquet |
|
|
|
|
|
|
| 15.00 |
L1
Nuovi approcci per
la somministrazione di anticorpi monoclonali |
SSS1
SIF-SISA Symposium: The
challenge of
innovation in
cardiovascular
medicine between the
unmet needs and the
sustainability of the healthcare system |
NS4
Taking rational decisions in a world of uncertainty: how to use pharmaco- economics for reimbursement of new drugs |
MS6
Alzheimer
disease: today’s update |
MS8
Stato attuale e
prospettive della farmacologia clinica dell’età pediatrica |
L21
New treatments of
Clostridium difficilis infections |
| 15.30 |
|
|
| 16.00 |
|
L15
Thermo-TRP inhibition: novel strategies to treat pain and more |
MS9
Quality of equivalent (generic) drugs |
| 17.00 |
NS20
Emerging role of the endocannabinoid signaling in
neuropsychiatric disorders |
C17 Oral
Communications
Pharmacology of Pain |
NS9
Clinical pharmacology and public health |
NS18
Alzheimer disease: identification of novel targets and therapeutic tools |
NS3
The need of Mitochondrial Pharmacology |
NS7
Enzymes regulating the intra- and extra-cellular activities of purines and their antineoplastic analogues |
NS22
Cardiac Stem Cells Ten Years Later: future developments |
| 19.00 |
Assemblea Collegio
Nazionale Farmacologi Universitari |
|
|
|
|
|
19.30
-
21.00 |
P1 Poster Session |
| October 25, 2013 |
| 8.30 |
C10 Oral
Communications
Cardiovascular Pharmacology 1 |
NS14
New research on neurodegeneration: time to translate it to clinic? |
NS21
Stress as a risk
factor for
neuropsychiatric disorders. Cognitive and metabolic aspects |
|
NS17
Nuovi bersagli farmacologici nella malattia di Parkinson |
NS6
Insights in purinergic signalling in normal and
pathological conditions of different cells and tissues |
|
| 10.00 |
|
|
|
L23
Rivaroxaban: dalle caratteristiche farmacologiche alle
evidenze cliniche nella
fibrillazione atriale e oltre |
|
|
|
| 10.30 |
Coffee break |
| 11.00 |
C18 Oral
Communications
Neuropsycho-pharmacology |
L9
Nuove soluzioni terapeutiche nell’ambito dell’antibioticoterapia: una valutazione degli
impatti farmacoeconomici |
L14
Clinical, social and economic evaluation of hypoglycemia in relation to the drug treatment |
L4
Preclinical
development and
clinical implications of mTOR inhibition in solid oncology |
MS11
Before, during
and after drugs: stay healthy while saving |
L17
Functional Gastrointestinal Disorders: Role of Guanylate Cyclase C agonist |
NS10
Rare diseases:
from gene to therapy: few bricks in the wall |
| 11.30 |
MS3
Innovation and sustainability in a time of financial crisis |
L22
Ivabradine: from pharmacological innovation to clinical benefits in heart failure |
L2
Pharmacological innovation in the treatment of skin cancer: from melanoma to basal cell carcinoma |
L19
New treatments for COPD:
pharmacological profile of Aclidinium Bromide |
| 12.00 |
|
L7
New immunological pathways: the role of IL-17 in psoriasis |
C16 Oral Communications
Pharmacology of the Respiratory Function |
|
| 12.30 |
L10
Clinical practice and antidepressive drugs |
L13
Tumore alla prostata: meccanismi di azione dei nuovi farmaci |
L12
Alginate
containing
formulations for the
management of
gastro-esophageal reflux |
| 13.00 |
Lunch |
| 13.30 |
P2 Poster session (area poster) |
| 15.00 |
L6
The pharmacological rationale of maximization of bronchodilation in COPD |
MS7
Adherence to
therapy and
sustainability: a new
paradigm for the future |
S2
Update in pharmacological
therapy of T2 Diabetes Mellitus |
L11
Analogs of insulin and relative clinical practice: which differences? |
C8 Oral Communications Neurogenesis |
C11 Oral
Communications Cardiovascular Pharmacology 2 |
|
| 15.30 |
C20 Oral
Communications
Gender Pharmacology |
|
|
| 16.00 |
MS2
Gender medicine. Increasing
appropriateness and sustainability through a sex-oriented approach |
NS27
SIF-EPHAR Symposium: New paths for the treatment of alcohol addiction |
L18
Role of iron in the treatment of anemia in chronic kidney disease |
|
17.00
-
19.00 |
Assemblea Generale della SIF |
|
|
|
|
|
|
| October 26, 2013 |
| 8.30 |
C19 Oral
Communications
Drugs of Abuse |
C7 Oral
Communications
Alzheimer Pharmacology |
NS24
Brain development and synaptic organization: regulation by intellectual disability genes and immune molecules |
C12
Oral Communications
Cardiovascular Pharmacology 3 |
C1 Oral
Communications
Pharmacognosy |
C14 Oral Communications
Receptors and
Transduction Signal Mechanisms |
C13 Oral
Communications
Antineoplastic Drugs |
| 10.30 |
Coffee break |
| 11.00 |
C15 Oral
Communications Neuropharmacology |
MS1
A new drug, today on the market… do we really know it? |
NS19
Fenotipizzazione della broncopneumo- patia cronica ostruttiva e terapia farmacologica personalizzata |
L5
Multiple Sclerosis: Mechanism of action of the new oral DMDs |
NS15
SIF-SIPHAR Symposium: Herbal products in research and practice: between lights and shadows |
C9 Oral
Communications Pharmacology of the Digestive Apparatus |
NS28
SIF/EBRA Joint Symposium: The use of animals for scientific purposes: which implications for Italian research? |
| 11.30 |
|
| 12.00 |
NS26
Simposio SIF- AIOM: La farmacogenetica come strumento di personalizzazione della terapia antitumorale |
|
| 12.30 |
|
| 13.00 |
Poster Awards |
|
|
|
|
|
|
